Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cardioxane (ADR-529) 是一种心脏保护剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 257 | 现货 | ||
10 mg | ¥ 413 | 现货 | ||
25 mg | ¥ 632 | 现货 | ||
50 mg | ¥ 813 | 现货 | ||
100 mg | ¥ 1,120 | 现货 | ||
200 mg | ¥ 1,660 | 现货 | ||
500 mg | ¥ 2,790 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 293 | 现货 |
产品描述 | Cardioxane (ADR-529) is a cardio-protective drug. |
体外活性 | Dexrazoxane (10 mM), known clinically to limit anthracycline cardiac toxicity, prevents daunorubicin-induced myocyte apoptosis, but not necrosis induced by higher anthracycline concentrations in rat cardiac myocytes. [1] Dexrazoxane presumably exerts its cardioprotective effects by either binding free or loosely bound iron, or iron complexed to doxorubicin, thus preventing or reducing site-specific oxygen radical production that damages cellular components. [2] Dexrazoxane specifically abolishes the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes. Dexrazoxane also induces rapid degradation of Top2beta, which paralleles the reduction of doxorubicin-induced DNA damage. Dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity. [3] Dexrazoxane is hydrolyzed to its active form intracellularly and binds iron to prevent the formation of superhydroxide radicals, thus preventing mitochondrial destruction. [4] |
体内活性 | Dexrazoxane combined with doxorubicin, daunorubicin, or idarubicin reduces the tissue lesions in B6D2F1 mice (expressed as area under the curve of wound size times duration) by 96%, 70%, and 87%, respectively. Dexrazoxane combined with doxorubicin, daunorubicin, or idarubicin results in a statistically significant reduction in the fraction of mice with wounds as well as the duration of wounds. [5] |
激酶实验 | HTRF assay: Homogeneous time-resolved fluorescence (HTRF) assay measures the signal generated by 2 components when they are in close proximity. The p53–MDM2 binding assay uses a biotinylated peptide derived from the MDM2-binding domain of p53 and a truncated N-terminal portion of recombinant human GST-tagged MDM2 protein containing the p53-binding domain. Proteins for crystal structure studies are expressed in E. coli strain BL21 using the helper plasmid pUBS 520 coding for the lacIq repressor and the rare tRNAArg [AGA/AGG]. For crystallization, the frozen protein is thawed and concentrated to 9.8 mg/mL using a Centricon concentrator (3,000 MW cutoff). The complex is then formed by combining the protein with a slight molar excess of the inhibitor (stock solution is 100 mM in DMSO) and this solution is allowed to sit for 4 hours at 4°C. Cryopreserved crystals are used to collect diffraction data on beamline X8C at the National Synchrotron Light Source at Brookhaven National Laboratory. |
别名 | ADR-529 Hydrochloride, ICRF-187 hydrochloride, ADR-529, 右雷佐生盐酸盐, Dexrazoxane HCl, Cardioxane hydrochloride, ICRF-187 |
分子量 | 304.73 |
分子式 | C11H16N4O4·HCl |
CAS No. | 149003-01-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 55 mg/mL (180.5 mM)
DMSO: 56 mg/mL (183.8 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 3.2816 mL | 16.408 mL | 32.8159 mL | 82.0398 mL |
5 mM | 0.6563 mL | 3.2816 mL | 6.5632 mL | 16.408 mL | |
10 mM | 0.3282 mL | 1.6408 mL | 3.2816 mL | 8.204 mL | |
20 mM | 0.1641 mL | 0.8204 mL | 1.6408 mL | 4.102 mL | |
50 mM | 0.0656 mL | 0.3282 mL | 0.6563 mL | 1.6408 mL | |
100 mM | 0.0328 mL | 0.1641 mL | 0.3282 mL | 0.8204 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cardioxane 149003-01-0 DNA Damage/DNA Repair Topoisomerase Dexrazoxane ICRF 187 ADR-529 Hydrochloride inhibit ICRF-187 hydrochloride Cardioxane Hydrochloride ADR-529 Inhibitor NSC-169780 Dexrazoxane hydrochloride ADR 529 右雷佐生盐酸盐 ICRF187 ADR 529 Hydrochloride NSC 169780 Dexrazoxane HCl ICRF 187 Hydrochloride NSC169780 Cardioxane hydrochloride ADR529 Hydrochloride ADR529 ICRF187 Hydrochloride ICRF-187 Hydrochloride ICRF-187 inhibitor